Dublin, Ireland-based Allergen had positive phase III results in its Viberzi study for treating irritable bowel syndrome with diarrhea, according to Wallstreet.org. The New England Journal of Medicine published the results in its Jan. 21 issue.
Here are five observations:
1. The FDA approved Viberzi at 75 mg and 100 mg for a 12-week treatment.
2. Patients suffering from IBS-D can take the pill twice a day.
3. Allergen's stock rose 0.49 percent during the last trading session, reaching $293.22.
4. The company outperformed the S&P 500 by 9.6 percent.
5. Allergen develops medical aesthetics, generic, branded generic, biosimilar and over-the-counter pharmaceutical products.